Literature DB >> 19035314

Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms as risk factors for hepatocellular carcinoma in a Korean population.

Sun Young Kwak1, Un Kyung Kim, Hyo Jin Cho, Hee Keun Lee, Hye Jin Kim, Nam Keun Kim, Seong Gyu Hwang.   

Abstract

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer death in South Korea, but genetic susceptibility factors of HCC have not been examined extensively. Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) play an essential role in both DNA synthesis and methylation and polymorphisms in the MTHFR gene, 677C>T, 1298A>C and the MTRR gene, 66A>G, are associated with several types of malignancy. In this study, the allelic frequencies and genotype distribution of three polymorphisms in the MTHFR and MTRR genes from 96 hepatocellular carcinoma (HCC) patients and 201 controls were examined to assess the association between these polymorphisms and the development of HCC in this Korean population. The 66AG+GG (G allele-bearing) genotype of the MTRR gene was significantly associated with an increased risk of HCC (odds ratio, OR, 1.687; 95% confidence interval, CI=1.022-2.787). Moreover, the combination of MTHFR 1298AA/MTRR 66AG+GG (OR=1.854, 95% CI=1.005-3.420) and MTHFR 1298AC+CC/MTRR 66AG+GG (OR=2.733, 95% CI=1.195-6.249) showed a significant association with HCC risk. In the data classified by age and etiology, MTRR 66A>G over the age of 65 years, MTHFR 1298A>C under the age of 65 years and the MTRR 66AG+GG genotype in the hepatitis B virus (HBV) patients were increased risk factors for the disease. The MTHFR 1298A>C and the MTRR 66A>G genotypes were associated with an increased risk of HCC in this Korean population. Further studies involving larger and varied populations could provide a potential tool for cancer risk assessment in patients who are at risk of developing HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19035314

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  Folate metabolism-related gene polymorphisms and susceptibility to primary liver cancer in North China.

Authors:  Lian-Hua Cui; Yang Song; Hongzong Si; Fangzhen Shen; Min-Ho Shin; Hee Nam Kim; Jin-Su Choi
Journal:  Med Oncol       Date:  2011-09-29       Impact factor: 3.064

2.  Association between MTHFR A1298C polymorphism and hepatocellular carcinoma risk.

Authors:  Haiyan Zhang; Guang Li; Zhen Zhang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  The MTHFR polymorphism affect the susceptibility of HCC and the prognosis of HCC liver transplantation.

Authors:  C Wang; H Xie; D Lu; Q Ling; P Jin; H Li; R Zhuang; X Xu; S Zheng
Journal:  Clin Transl Oncol       Date:  2017-11-28       Impact factor: 3.405

4.  Quantitative assessment of the association between MTHFR rs1801131 polymorphism and risk of liver cancer.

Authors:  Tie-Jun Liang; Hui Liu; Xiao-Qian Zhao; Yan-Rong Tan; Kai Jing; Cheng-Yong Qin
Journal:  Tumour Biol       Date:  2013-09-08

5.  Associations between MTHFR Ala222Val polymorphism and risks of hepatitis and hepatitis-related liver cancer: a meta-analysis.

Authors:  Ruiying Zheng; Wenyuan Zhao; Dongwei Dai; Chengzhong Li
Journal:  Tumour Biol       Date:  2013-10-24

6.  Methionine synthase reductase A66G polymorphism contributes to tumor susceptibility: evidence from 35 case-control studies.

Authors:  Dong Han; Chao Shen; Xiangning Meng; Jing Bai; Feng Chen; Yang Yu; Yan Jin; Songbin Fu
Journal:  Mol Biol Rep       Date:  2011-05-06       Impact factor: 2.316

Review 7.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

8.  Significant association between MTHFR C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis.

Authors:  Hongli Sun; Bing Han; Hongpeng Zhai; Xinhua Cheng; Kai Ma
Journal:  Tumour Biol       Date:  2013-10-17

9.  Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells.

Authors:  Guat-Siew Chew; Stephen Myers; Alexander Chong Shu-Chien; Tengku Sifzizul Tengku Muhammad
Journal:  Mol Cell Biochem       Date:  2013-11-16       Impact factor: 3.396

10.  Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis.

Authors:  Fei Jin; Li-Shuai Qu; Xi-Zhong Shen
Journal:  Diagn Pathol       Date:  2009-11-24       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.